Wednesday, 29 October 2014

Worldwide Coagulation Testing Industry Segments Growth: Point-of-Care Coagulation Testing and Home Diagnostics

Coagulation tests help in measuring the clotting ability of blood. Clotting is the process of blood converting from liquid into gel form. Coagulation tests are performed to analyze clotting disorders such as hemorrhage and thrombosis. Coagulation tests include complete blood count, factor V assay, fibrinogen level, prothrombin time, platelet count, thrombin time, and bleeding time. Coagulation testing analyzers play a major role in improving patients’ quality of life.

Analysts forecast the Global Coagulation Testing market to grow at a CAGR of 5.62 percent over the period 2013-2018.

The report recognizes the following companies as the key players in the Global Coagulation Testing Market: Abbott Laboratories, Danaher Corp., Roche Diagnostics and Sysmex Corp.

Other Prominent Vendors in the market are: Alere, Cepheid, CoaguSense, Helena Laboratories, HYPEN BioMed, LABiTec, Medtronic, Siemens, Sienco and Stago.

An expansion of some of the economies in the APAC region is one of the main trends seen in this market. Governments in emerging countries are making efforts to improve healthcare infrastructure, which has benefited the Coagulation Testing market.

Covered in this Report
The Global Coagulation Testing market can be segmented into the revenue generated from end- user application such as: Point-of-Care Coagulation Testing and Home Diagnostics.

Global Coagulation Testing market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Coagulation Testing market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

According to the report, one of the major drivers in the market is the increase in the prevalence of cardiovascular disease. CVD deaths occur almost equally in men and women and it is predicted that by 2030 almost 23.6 million people will die from CVD. An increase in the prevalence of CVD has led to the development of coagulation testing products, and thus, the growth of the market.

Further, the report states that one of the major challenges in the market is the high cost incurred in R&D activities. Many big vendors are facing the frequent elimination of coagulation testing analyzer products because of rapid developments with respect to the technological aspects of coagulation testing analyzers.

Single User License of the Report is Available at USD 2500, Buy the Report @ .